



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

Publication number

0 156 641  
A2

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number 85302045 1

(22) Date of filing. 25.03.85

(51) Int. Cl.<sup>4</sup>: G 01 N 33/58  
G 01 N 33/53, C 12 Q 1/34  
//C12Q1/68

(30) Priority. 26.03.84 GB 8407736

(43) Date of publication of application:  
02.10.85 Bulletin 85/40

(84) Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE

(71) Applicant: UNIVERSITY COLLEGE LONDON  
Gower Street  
London WC1E 6BT(GB)

(72) Inventor: Rabin, Brian Robert  
34 Grangewood Potters Bar  
Hertfordshire(GB)

(72) Inventor: Taylorson, Christopher John  
31 Bath Road  
Chiswick London, W4(GB)

(72) Inventor: Hollaway, Michael Robert  
214 Ember Lane  
East Molesey Surrey(GB)

(74) Representative: Armitage, Ian Michael et al,  
MEWBURN ELLIS & CO. 2/3 Cursitor Street  
London EC4A 1BQ(GB)

(54) Enzymic method of detecting analytes and novel substrates therefor.

(57) A small enzymically inactive peptide fragment of an enzyme (e.g. ribonuclease S-peptide) is used as the label and conjugated with the complementary fragment (S-protein) to form an enzyme which catalyses a primary reaction whose product is, or leads to, an essential coenzyme or prosthetic group for a second enzyme which catalyses a secondary reaction leading to a detectable result indicating the presence of analyte. Also disclosed are novel synthetic substrates for the primary reaction. Substrates for ribonuclease S conjugate enzyme are of the formula R-X where R is a pyrimidine 3'-phosphate moiety and X is a leaving group linked to R through the 3'-phosphate group and leads to said coenzyme or prosthetic group, e.g. via riboflavin, thiamine, pyridoxal, pyridoxine or pyridoxine phosphate

EP 0 156 641 A2

09/3/707  
2013/11/07

ENZYMIC METHOD OF DETECTING ANALYTES AND  
NOVEL SUBSTRATES THEREFOR

This invention relates to methods for detecting  
5 analytes in sample media by means of enzymic reactions.  
It is particularly, but not exclusively, applicable to the  
detection of polynucleotide analytes.

Nucleic acid hybridisation assays are of increasing  
practical importance for the diagnosis of, and the detection  
10 of carriers of, human inherited diseases (for example, see  
Banbury Report 14, Recombinant DNA Applications to Human  
Diseases, ed. S.T.Caskey & R.L.White, Cold Spring Harbor  
Laboratory, 1983). They are valuable also for the identifi-  
cation of pathogenic organisms, including viruses and  
15 bacteria, and for identification of genes conferring  
resistance to antibiotics in the latter.

Commonly used procedures involve the use of radio-  
chemically-labelled probes with the attendant problems of  
safety, cost and limited shelf-life. Alternative methods of  
20 detection have been proposed in which a chemiluminescent,  
fluorescent or phosphorescent material is attached to the  
probe (EP 70687), but it is doubtful whether such methods  
have the sensitivity required to detect the presence of the  
10<sup>-18</sup> moles of a single copy gene typically available for  
25 determination.

Another approach has been to attach the probe to biotin  
and use avidin coupled to a suitable enzyme for the purpose

of detection (GB 2019408). The sensitivity of this method is limited by the number of molecules of the detector enzyme that can be attached to avidin.

EP 27036 proposes an assay system using a conjugate between a probe and an enzyme, the enzyme then taking part in a primary reaction which produces or removes a "modulator" for a secondary reaction system; the modulator being a substance which gives rise to a catalytic event in the secondary reaction system, but of which there is no net consumption during the catalytic event. This therefore gives rise to an amplification factor between the primary and secondary reaction systems. The modulator may be an enzyme activator or inhibitor, or a cyclicly regeneratable substrate for the secondary system.

Assay systems using secondary reactions to achieve amplification are likewise disclosed in WO 81/00725, which refers to the use of cyclising substrates, and in EP 49606, which refers to the primary reaction producing a "facilitator" which enhances the rate of the secondary reaction.

In enzyme-linked immunoassay systems it is usual for the labelling enzyme to be conjugated to the probe, and this means that excess enzyme has to be removed very efficiently before the enzyme-catalysed reaction takes place, otherwise a false positive result is obtained. This gives rise to considerable problems, and a high signal/noise ratio is difficult to obtain.

EP 62277 discloses the use of an enzyme based on ribonuclease A. Ribonuclease A can be split into a 20 residue polypeptide, called the S-peptide, and a 104 residue polypeptide, called the S-protein. Neither the S-peptide nor 5 the S-protein alone has enzymic activity, but they will form a conjugate, called ribonuclease S, which has ribonuclease activity. The proposal in the above disclosure is to label an analog of the analyte with the S-peptide, so that the assay medium contains labelled analog and unlabelled analyte.

10 An antibody is then introduced which can attach itself either to the analyte molecules or to the analog molecules. The analyte thus competes with the analog for binding antibody, and S-peptide on unbound analog molecules are then free to combine with added S-protein and produce enzymic 15 activity. By adding increasing concentrations of the analyte, a displacement curve is constructed which relates catalytic activity to analyte concentration, and it is proposed that this reference curve be used to determine unknown analyte concentrations. The ribonuclease S activity 20 is typically carried out using spectrophotometric or fluorometric techniques. This method of using the S-peptide/S-protein combination appears complicated and difficult, and in principle the determination of analyte by measuring differences in reaction rate would appear to 25 impose limitations on sensitivity, accuracy and ease of execution.

One aspect of the present invention provides a method

of detecting an analyte in a sample medium, involving the use of an assay component carrying an enzymically inactive small fraction of a primary enzyme, and the addition of a complementary enzymically inactive protein fraction of the 5 enzyme so as to conjugate to said small fraction and produce an active primary enzyme, and the performance of a reaction catalysed by said enzyme, leading to a detectable result; characterised in that said assay component is a specific recognition probe which binds to the analyte, and said 10 primary enzyme catalyses a reaction which converts a substrate into a primary product which itself, or as a subsequent product produced by a further reaction or series of reactions initiated by said primary product, is a component essential for the catalytic activity of a second enzyme 15 which is thereby completed and catalyses a reaction leading to a detectable result.

Said small fraction of the primary enzyme is preferably a minor peptide fraction of the total enzyme protein. Such a small peptide fraction can be inert to the binding conditions, whereas a complete enzyme could have its activity 20 seriously affected by the conditions, such as extremes of temperature, pH, salt concentration, etc. Suitably it is a ribonuclease S-peptide, and the complementary fraction is the ribonuclease S-protein. The resulting ribonuclease S 25 enzyme then suitably catalyses the conversion of a synthetic substrate to said primary product. The synthetic substrate is suitably a pyrimidine 3'-phosphodiester compound of the

formula R-X, where R is a pyrimidine 3'-phosphate moiety and X is a leaving group which forms said primary product, X being linked to R' through the 3'-phosphate group. R can therefore be represented as Cp or Up, where C = cytidine, U = uridine and p = phosphate, or pyrimidine analogs thereof, and optionally substituted, e.g. with a 5'-hydroxy protecting group.

An advantage of the present invention over the prior proposals is that it provides a simple and direct method of enzymically detecting the analyte, with high sensitivity resulting from the secondary amplification, and high signal to noise ratio resulting from the fact that neither of the enzyme fractions (e.g. S-peptide and S-protein) have enzymic activity which can give rise to background "noise", so that the specific enzymic activity only arises from conjugate catalyst produced by bound S-peptide, and there is no need to remove excess of the larger enzyme protein fraction.

Synthetic substrate compounds such as R-X (which may be referred to as "prosthetogens") are thought to be novel per se. Therefore another aspect of the present invention provides a synthetic prosthetogen compound which is cleavable by an enzyme to produce a component essential for the catalytic activity of another enzyme, or a precursor therefor. Preferably, the prosthetogen is a pyrimidine 3'-phosphodiester compound of the formula R-X, where R is a pyrimidine 3'-phosphate and X is a leaving group linked to R through the 3'-phosphate group, and enzymically cleavable

therefrom to produce an essential component of another enzyme, or precursor therefor.


Another aspect of the invention is an enzyme linked immunoassay procedure in which a primary enzyme whose 5 concentration is related to the presence of analyte to be detected catalyses a primary enzymic reaction leading to a detectable product; characterised in that a substrate for the primary enzyme is a synthetic compound which is cleaved by the primary enzyme to produce directly, or by one or more 10 further reactions, a component essential for the catalytic activity of another enzyme, which is thereby activated to catalyse a secondary enzymic reaction leading to a detectable result.

The present invention thus employs the principle of an 15 enzyme-linked detection system, but an enhancement in the sensitivity of many orders of magnitude is obtained by using the primary catalyst to generate, directly or indirectly, a coenzyme or prosthetic group that is part of another and different catalytic centre employing an enzyme which depends 20 absolutely on said coenzyme or prosthetic group for catalytic activity. The primary enzymic reaction can therefore produce a coenzyme or prosthetic group directly, or it can produce a precursor which is then converted, e.g. enzymically, to the coenzyme or prosthetic group. The 25 coenzyme or prosthetic group, whether produced directly or indirectly, is then combined with a suitable apoenzyme to produce a holoenzyme, the quantity of which can be assayed

by using the holoenzyme to catalyse a secondary reaction system leading to a detectable result, such as the formation of a dye.

A preferred assay procedure is shown in Scheme 1 below.

SCHEME 1



All catalysts are boxed and placed above an arrow indicating the reaction catalysed. The primary enzyme is  $E_0$  and the detecting active holoenzyme  $E_{2a} X'$ .


The probe is attached to a component A<sub>1</sub> in a manner so as not to interfere with hybridisation, preferably at either of the free ends of the probe, by a suitable spacer group using, for example, the methodology described in Nucleic 5 Acid Research, Vol.11 (1983) pp.659-669. Following hybridisation under appropriate stringency conditions, addition of A<sub>2</sub> gives an enzymically active species, A<sub>1</sub>A<sub>2</sub>, designated E<sub>0</sub> in Scheme 1, attached to the probe. This is the Recognition Phase of the invention. This primary enzyme, E<sub>0</sub>, acts catalytically whilst immobilised to the target DNA on a 10 prosthetogen substrate R-X to release the coenzyme or prosthetic group precursor X-OH which, in turn, following conversion where necessary to the active form of the coenzyme X' in a process catalysed by the enzyme E<sub>1</sub>, 15 combines with an inactive apoenzyme E<sub>2i</sub> to give the enzymically active detecting holoenzyme E<sub>2a</sub>X'. In some cases the E<sub>0</sub>-catalysed reaction will produce a coenzyme or prosthetic group directly, in which case the conversion step using enzyme E<sub>1</sub> is omitted. The enhancement in sensitivity 20 arises from the fact that, in principle, every molecule of X' produced can give rise to an active molecule of E<sub>2a</sub>X', and that the number of molecules of E<sub>2a</sub>X' produced will exceed greatly that of E<sub>0</sub> attached to the probe. In this invention X' is part of the catalytic centre of enzyme E<sub>2a</sub>X' 25 and is not an allosteric activator of the substrate. It is absolutely required for catalytic activity, and is not a mere rate enhancer for an existing enzymic reaction, as is

the case with some of the prior art proposals. Enzyme E<sub>2a</sub>X' catalyses the formation of an easily detected product P from a substrate S.

An example of the invention employs as the A<sub>1</sub> and A<sub>2</sub> fragments, S-peptide (S<sub>pep</sub>) and S-protein (S<sub>pr</sub>), respectively, derived from bovine pancreatic ribonuclease (EC 3.1.27.5) by proteolytic cleavage with subtilisin (EC 3.4.21.14). It is well known that the enzymically inactive S-peptide and S-protein can combine with very high affinity 10 to generate ribonuclease S which has full ribonuclease A enzymic activity.

The active hybridised probe-A<sub>1</sub>-A<sub>2</sub> complex (hybridised probe-enzyme E<sub>0</sub>) acts on the prostheticogen substrate R-X which, for example, has the form CpX or UpX where X would be 15 linked through a 3'-phosphodiester linkage (p) to cytidine (C) or uridine (U) nucleoside. The "leaving group" X-OH is a prosthetic group or coenzyme precursor, such as thiamine, riboflavin, pyridoxal or pyridoxine.

It is well known that bovine pancreatic ribonuclease A 20 catalyses the following reactions:



where, although X-OH must be a primary alcohol, there are few other restrictions on its structure in order to act as a 25 suitable leaving group in the ribonuclease-catalysed reaction. (For a review see F.R.Richards and H.W.Wyckoff, in "The Enzymes", Vol.3, 3rd Edition, 1971, ed. P.D.Boyer,

pp.647-806)

Some examples of the nature of the various components that may be employed in Scheme are given in Table 1.

5

6

TABLE 1

10

<u>X-OH</u>	<u>E<sub>1</sub></u>	<u>X'</u>
Riboflavin	Riboflavin kinase (EC 2.7.1.26)	Flavin mononucleotide (FMN)

15

Riboflavin	Riboflavin kinase (EC 2.7.1.26)	Flavin adenine dinucleotide (FAD)
	+	
	FMN Adenyl transferase	
20	(EC 2.7.7.2)	

Thiamine	Thiamine pyrophosphokinase	Thiamine diphosphate
25	(EC 2.7.6.2)	

Pyridoxal

Pyridoxal kinase

Pyridoxal 5-phosphate

(EC 2.7.1.35)

5 Pyridoxine

Pyridoxine

Pyridoxal 5-phosphate

4-dehydrogenase

(EC 1.1.1.65)

+

Pyridoxal kinase

10

(EC 2.7.1.35)

Pyridoxine  
phosphatePyridoxine  
4-dehydrogenase

Pyridoxal 5-phosphate

15

(EC 1.1.1.65)

20

Suitable apoenzymes to produce enzyme  $E_{2a}X'$  from  $X'$  will be obvious to workers skilled in the art, as will systems for the detection of P by colour production, fluorescence or luminescence (see, for example, H.Harris and D.A.Hopkinson, *Handbook of Enzyme Electrophoresis in Human Genetics*, 1976, North-Holland Publishing Co.).

The invention can be further understood from the

following more detailed description, which is given by way of example, and should not be regarded as limiting the scope of the invention.

5    A - THE PROBES

Oligonucleotide probes with the required base sequences for hybridising with polynucleotide analytes can be synthesised by the solid phase, phosphotriester method on a 10 keiselguhr-polydimethylacrylamide support, as described in detail by Gait et al [M.J.Gait et al 1982].

The detection system can also be applied in procedures other than those involving gene probes. Thus, in principle, any antigen-antibody interaction could be monitored with 15 greater sensitivity than current non-radioactive methods, using the present invention.

B - SYNTHESIS OF PROBE-S-PEPTIDE DERIVATIVES

20    Conventional and routine procedures can be used for linking S-peptide to probe molecules. Such procedures are discussed in EP 62277. Likewise that disclosure refers to the use of modifications to, or analogs of, the Spep-Spr subtilisin cleavage products of ribonuclease A, and also to 25 other cleavable enzymes. The present invention similarly comprehends such variants.


Methods for preparation of RNase S and the separation

into S-peptide and S-protein have been described by Doscher (1969) and Chavers & Scheraga (1980) respectively.

Reaction of the bifunctional reagent SPDP (n-succinimidyl 3-(2-pyridyldithio)propionate) with the S-peptide gives a derivative containing one mole of reagent per mole of peptide. Substitution at the  $\alpha$ -amino group of the N-terminal lysine is a preferred position, as this residue does not contribute significantly to the S-peptide - S-protein interaction.


10

15



20

This derivative, I, is reactive towards thiol reagents and so can be employed to couple an oligonucleotide that has been "G-tailed" by the method of Roychoudhury et al (1976) and reacted with N-acetyl-N'-(p-glyoxylbenzoyl)cysteamine according to the methods of Cheng et al (1983). The reaction scheme is as follows.





5


10

The use of compound II to detect the presence of DNA containing sequences complementary to those in the probe can be represented as follows.

15



20



25

where the zig-zig lines represent the complementary sequences of the probe and target sequences in the DNA.


Reaction (ii) can be regarded as optional but may offer advantages in that the S-peptide fragment bears only the 5 relatively small  $\beta$ -mercaptopropionyl group, which would be less likely to diminish enzymic activity than the large probe-DNA complex. This step offers the additional advantage that the S-protein - S-peptide complex would be freed from the matrix to which the DNA has been immobilised.

10

C - ENZYMIC DETECTION SYSTEMS FOR THE PROBE-S-PEPTIDE DERIVATIVE

A detection system giving a coloured solution or spot 15 on a supporting matrix is preferred as this will simplify and so widen the application of the technology. Greater sensitivity, however, can be achieved by the use of specialised instruments such as luminescence monitors, fluorometers or spectrophotometers.

20 A general reaction sequence for the system is as follows:



5

10

wherei::

P-S<sub>pep</sub>: probe-S-peptide derivative.

S<sub>pr</sub>: the S-protein derived from RNase.

15 S<sub>1C<sub>1</sub></sub>: a phosphodiester substrate for RNase containing the coenzyme or coenzyme precursor C<sub>1</sub>' as the leaving group.

Modifying enzymes: active enzymes which generate the form of the coenzyme required for combination with Apo 1.

20

Apo 1: the enzymically inactive apoenzyme for which C<sub>1</sub> is the coenzyme.

Holo 1: the active holoenzyme formed by combination of Apo 1 with the coenzyme C<sub>1</sub>.

25

S<sub>2</sub>: the substrate for Holo 1 which gives the coloured product P\*.

Enzymically active components are shown as enclosed in rectangles with dotted arrows pointing towards the reactions catalysed.


The S-peptide:S-protein interaction

The system exploits the tight and specific binding of the S-peptide to the S-protein. This interaction is of such high affinity that it has not proved possible to determine a value for the dissociation constant ( $K_{diss}$ ), but an upper limit of  $K_{diss}$  has been put at  $5 \times 10^{-9}$  M by Richards & Vithayathil (1959 a,b). Thus with a concentration of S-protein catalyst of  $10^{-7}$  M or less, 95% of the probe would be converted to primary catalyst. RNase S exhibits enzymic activities that are very similar to those of the native RNase A [Takahashi et al (1969)].

In the following presentation specific proposals are made for the nature of the coupling coenzyme,  $C_1$ , and final detection system ( $S_2 \longrightarrow P^*$ ). However there is a large number of alternative possible processes based on other coupling coenzymes and other visualisation procedures.

The detection system with riboflavin as the coupling 20 coenzyme


In this case the substrate for enzymic action by the probe-S-peptide - S-protein complex would be of the following type (III).



where C = cytosine (or other pyrimidine base).

15 Synthesis of substrate III (Cp Riboflavin)

The substrate Cp riboflavin can be prepared by taking advantage of the reversibility of the first step of ribonuclease A action to synthesise a substrate III consisting of cytidine linked via a 3' phosphate moiety to the terminal hydroxyl residue of the ribityl side chain of riboflavin.



Because of the high hydrolytic activity of RNase A, only small yields of substrate would be expected if the reaction 10 were carried out in aqueous solution. Therefore the reaction was carried out in 50% formamide at -20°C, with the highest possible concentration of riboflavin as the attacking group, with the requisite primary alcoholic group as the nucleophile.

15

### Experimental

#### I. Enzyme catalysed production of Cp Riboflavin

20

The reaction was performed at -20°C with 600 mg of cytidine 2',3'-cyclic phosphate, 1 g of riboflavin and 1 mg/ml ribonuclease A in a total volume of 1130 mls of 50% v/v formamide/buffer pH 6.50.

25 (The reaction mixture must be maintained away from the light and on the acid side of neutrality to avoid the breakdown of riboflavin to lumiflavin.)

Progress of the reaction was monitored by using thin

layer chromatography. Aliquots (100  $\mu$ l), were withdrawn at regular intervals (5 days) and chromatographed on Whatman PLK SF silica gel plates against standards, (5  $\mu$ g), of riboflavin, cytidine 2',3'-cyclic phosphate and cytidine 5 adenosine phosphodiester (CpA). (Figure 1)

The solvent used was  $H_2O$ , 40 : pyridine, 10 : glacial acetic acid, 1; pH 5.80.

Product began to appear on the chromatographs after 11 days of incubation as a spot with an  $R_f$  value of 0.87 10 compared to the  $R_f$  values of 0.79 for riboflavin, 0.95 for cytidine 2',3'-cyclic phosphate and 0.89 for CpA. The reaction was stopped after 31 days when the predominant spot on chromatographs was that at  $R_f$  0.87.

### 15 III. Stopping the reaction

It was essential at this point to inactivate the 20 ribonuclease in the incubation mixture as exposure of the product to the enzyme in an aqueous environment would result in its breakdown to cytidine 3'-phosphate and riboflavin.

Therefore, ribonuclease was removed by phenol extraction of the incubate at pH 5.40.

The incubate was extracted with phenol three times and the combined aqueous phases were extracted once with chloro- 25 form. This procedure had the added advantage in that it facilitated the removal of a large percentage of the formamide present in the reaction mixture.

The combined aqueous phases were reduced in volume by rotary evaporation at 55°C prior to separation of product from unreacted riboflavin and cytidine 2',3'-cyclic phosphate on columns of silica gel.

5

III. Separation of product from unreacted constituents  
(flash chromatography)

The separation of product from unreacted riboflavin and 10 cytidine 2',3'-cyclic phosphate was effected using intermediate pressure chromatography (Still et al, 1978).

An aliquot of the phenol and chloroform extracted incubate from stage II (10 ml) was applied to a column of 15 silica gel (Merck silican gel 60) and eluted in  $H_2O$ , 40 : pyridine, 10 : glacial acetic acid, 1, under a positive pressure of oxygen free nitrogen 15 lbs/in<sup>2</sup> (1.05 kg/cm<sup>2</sup>). (Figure 2)

Fractions were pooled and assayed by thin layer chromatography as described previously. (Figure 3)

20 Fraction A (Figure 2 and track 4 Figure 3) was tested as a substrate for ribonuclease by incubating an aliquot (100  $\mu$ l) in a mixture containing 2 mg of ribonuclease in a final volume of 1 ml of 0.1 M ethylene diamine buffer pH 6.50 for 2 hours at room temperature. The resultant 25 chromatogram showed that the spot at Rf 0.87 was resolved into 2 spots of Rf 0.79 (riboflavin) and 0.96 (cytidine 3'-phosphate), indicating that the product was hydrolysed by

RNase into its constituent components. (Figure 4)


Fraction A (Figure 2) was pooled and rotary evaporated at 55°C to obtain a solid. However, a residual volume of formamide remained which was not removed during the phenol extraction protocol and which moved with the mobile phase during intermediate pressure chromatography. Removal of the formamide provides the substrate in solid form.

#### 10 Primary Reactions


The desired active form of the coenzyme, FMN, is generated by the action of riboflavin kinase (flavokinase: EC 2.7.1.26) an enzyme that is readily prepared.

15 There are many candidates for the detecting enzyme employing FMN as the coenzyme, including glycolate oxidase [EC 1.1.3.1 Schuman & Massey (1971)] from which FMN can be removed by dialysis against 1 M KBr [Massey & Curti (1966)]; L-hydroxyacid oxidase [EC 1.1.3.15, Nakano et al (1968)] and 20 orotate reductase from Zoroticum [EC 1.3.1.14, Swell et al (1960)], but a particularly preferred one is pneumococcal L-lactate oxidase [EC 1.13.12.4, Udaka et al (1959)].


This enzyme catalyses reaction (i):



25 which is inconvenient for assay purposes. However in the presence of catalase the reaction becomes [Udaka et al (1959)]:



Thus the enzymic reaction is:



5 This presents the opportunity of coupling the reaction to one of the rapid and sensitive methods for detecting  $\text{H}_2\text{O}_2$ , such as the reaction with the chromogenic substrates, 5-aminosalicylic acid or dianisidine, catalysed by horse-radish peroxidase [Kas & Cerna (1980)].

10 An alternative is to couple the production of FMN to the generation of flavodoxin. Apoflavodoxin is a well-documented detector for FMN or FAD in a system in which the extent of the change in fluorescence of the flavin nucleotide on combination with the apoprotein is used to determine 15 the amount of the nucleotide in an unknown solution [Mayhew & Wassink (1980):a & b]. However the fluorescence method would be insufficiently sensitive for the present purposes, so an enzyme-linked assay can be used e.g. the flavodoxin-mediated reduction of cytochrome c by NADPH catalysed by the 20 purified reductase [Shin (1971)].

Although FMN-coupled enzymes are proposed for the coenzyme coupling assays described above, the range of enzymes that could be employed can be expanded to those using FAD as coenzyme. This would involve the extra reaction 25 catalysed by FMN adenyltransferase: [Gibson et al (1955 and Schrecker & Kornberg (1950)]



where the FMN would have arisen from the flavokinase reaction.

This would enable, for example, D-amino acid oxidase to be employed as a coupling enzyme. The apoenzyme from this 5 oxidase is prepared readily by the KBr dialysis method [Massey & Curti (1966)] and is stable for at least several months if stored at -20°C. The assay of D-amino acid oxidase by coupling with a peroxidase-catalysed reaction is well-documented and offers the opportunity of a chromogenic 10 visualisation of the enzyme [Tsuge & Nakanishi (1980)].

Other FAD enzymes could be employed in similar fashion including glucose oxidase; L-amino acid oxidase and xanthine oxidase [Tsuge & Nakanishi (1980)]. It remains to be established which system would be the most favourable but 15 each of these enzymes is readily available and can be treated to give stable apoenzymes.


The detection system using pyridoxal phosphate as the coupling coenzyme

20

Aspartate aminotransferase (EC 2.6.1.1) catalyses the reaction of  $\alpha$ -oxoglutarate ( $\alpha$ OG) with (S)-aspartate (Asp) to form oxaloacetic acid (OAA) and (S)-glutamate (Glu). The enzyme contains pyridoxal phosphate as a coenzyme and the 25 holo enzyme can be readily and reversibly resolved into free coenzyme and apoenzyme [Martinez-Carrion et al 1970]. A sensitive assay for the holoenzyme (nanomolar concentra-


tions) has been described by Raj (1982) based on the formation of a coloured reduced neotetrazolium derivative INT\* red coupled to the reaction catalysed by glutamate dehydrogenase.

5 A procedure for probe-S-peptide detection using aspartate aminotransferase as Holo 1 is as follows:



where  $S_1C_1$  is a cytidine 3'-phosphodiester with pyridoxal (Py), pyridoxamine or pyridoxal as the  $C_1$  moiety.


A possible substrate ( $S_1C_1$ ) for RNase action giving pyridoxal as one of the products is compound IV which is hydrolysed as follows:




Compound IV can be synthesised by a procedure similar to that published for Cp benzyl [Bernard & Witzel 1961]. Pyridoxal, shown as the hydrate, formed by the above reaction, is converted to the pyridoxal phosphate required in 15 the reaction catalysed by pyridoxal kinase (EC 2.7.1.35).

Other possible substrates include compounds V - VII:

20




V



VI

25



VII

where Cp represents cytidine 3'-phosphoryl- and R is either H- or -O-P(OH)2.

Compound V on hydrolysis by RNase S would give pyridoxol, which is converted to pyridoxal using pyridoxol oxidase (EC 1.4.3.5) in the assay system as an additional 5 step before the kinase-catalysed reaction. If compound VI, the phosphorylated form of compound V, is used as a substrate for RNase S, pyridoxal phosphate would be generated directly by the action of the oxidase. Compound VII, in 10 which the cytidine 3'-phosphoryl group is in a phosphodiester link at the phenolic oxygen of pyridoxal, under RNase-catalysed hydrolysis would likewise give pyridoxal phosphate directly. However it is known that the enzymic specificity 15 is such that bulky substituents on the oxygen atom of the leaving group are poorly tolerated so this substrate may be less preferred.

Compounds V and VI can be prepared enzymically by using RNase to catalyse the condensation reaction in formamide/water or other aprotic solvent/water mixtures [Findlay, 20 Mathias & Rabin (1962)]. Chemical synthesis using a phosphotriester-based approach with suitably protected reactants may be employed to synthesise compound VII as well as compounds V and VI.

A preparation of the apoenzyme apo glutamic-aspartic 25 transaminase (Apo 1) has been described [Martinez-Carrion


(1970), Arrio-Dupont M. (1972)] and is best carried out in stages: first replacing the pyridoxal-phosphate with the less affine pyridoxamine phosphate and then removing the latter by using gel chromatography. The apoenzyme is stable 5 for long periods. Removal of all the pyridoxal phosphate is essential for good signal-to-noise ratio but this is ensured by an inhibition step involving treatment with a ketoacid and then  $\text{NaBH}_4$ , which inactivates any residual enzymic activity in the preparation of the apoenzyme.

10       Reconstitution of Holotransaminase from pyridoxal phosphate and the apoenzyme has been described in an elegant paper by M. Arrio-Dupont (1972). Typically, a concentration of apotransaminase of 0.1  $\mu\text{M}$  or greater is employed. This concentration is sufficient to ensure essentially 15 stoichiometric conversion to holotransaminase of any low concentration of pyridoxal phosphate formed in the system.

#### A DOUBLE AMPLIFICATION SYSTEM USING DOUBLE COENZYME COUPLING

20       It is clear that in principle "cascades" can be built up to make the assay systems as sensitive as required.

      A potentially very sensitive system is described below. The double amplification arises from the primary catalyst releasing a coenzyme (eventually FAD) which combines with 25 an apooxidase to generate a second coenzyme, pyridoxal phosphate, which in turn activates the second apoenzyme.



20 PROBE-ENZYME CLEAVAGE

As indicated above, one aspect of the procedure of the invention lies in the possibility of removing the primary enzyme ( $E_0$  in scheme 1) from the detection system prior to carrying out the primary enzymic reaction. This has the advantage that the primary reactions, sensitivity

enhancement and detection can be carried out in free solution away from the polynucleotide analyte and oligonucleotide probe. This cleavage of the probe-enzyme fraction bond can be effected prior to conjugating the 5 larger enzyme fraction to complete the enzyme, or after conjugation but before adding the substrate. By way of example: if the analyte is a polynucleotide, the probe is an oligonucleotide hybridisable therewith, and the smaller enzyme fraction is S-peptide linked to the oligonucleotide 10 through a disulphide bond; this bond can be cleaved using conventional reducing agents such as dithiothreitol or  $\beta$ -mercaptoethanol to release the S-peptide once more. Thus, Spep-probe can be added to the sample, and unbound Spep-probe removed by washing. Then the S-peptide is cleaved 15 from the probe and reacted with excess S-protein to form the enzyme conjugate; or else the S-protein can be added to the Spep-probe followed by cleavage of the conjugate from the probe. A specific example could involve: (i) immobilising the analyte on a support, such as a polymeric or absorbant 20 solid; (ii) reacting the immobilised analyte with excess Spep-probe in solution; (iii) removing the support with its bound analyte-Spep-probe complex from the solution, and washing to remove any unbound Spep-probe; (iv) immersing the support in a solution of a cleaving agent which cleaves the 25 Spep from the support so that it goes into solution; (v) adding S-protein to the solution to form the enzyme conjugate, and carrying out the enzymic reactions to produce

the detectable result. Step (v) could involve the single addition to the solution of all the other reagents, along with the S-protein, to complete the assay reactions. As an alternative, the S-peptide could be initially immobilised on 5 a support, so that the subsequent cleavage step removes the analyte and probe, leaving the S-protein to conjugate with the S-peptide on the support. In this way the primary enzymic reaction, and possibly the subsequent reactions, can take place on the support, which could be easier and more 10 sensitive for identifying the detectable result of the reactions.


The separation of the primary enzyme from the probe prior to carrying out the primary enzyme catalysed reaction could be advantageous in that the probe and analyte will 15 then not interfere with the activity of the enzyme. Likewise, cleaving the small enzyme fraction (S<sub>pep</sub>) from the probe before conjugating it with the larger fraction (S<sub>pr</sub>) avoids the probe or analyte interfering with the conjugation.

## 20 Prosthetogens

The concept of synthetic prosthetogens can be applied more generally than in the specific examples illustrated above. For instance, ribonuclease (RNase) can be used as a 25 primary enzyme linked indirectly to the probe such as by a biotin-avidin linkage as described in GB 2019408. The RNase can then act on the novel synthetic prosthetogen R-X

substrate described above to give a coenzyme precursor, leading ultimately to a detectable result via the secondary enzymic reaction.

Moreover, the primary enzyme for the prosthetogen reaction need not be RNase. Starting with a suitable coenzyme or prosthetic group for the secondary reaction, a reaction scheme is formulated having as a primary reaction the enzymically catalysed cleavage of a synthetic starting material (the novel prosthetogen). For example the prosthetogen may be an acylated coenzyme and the primary enzyme an esterase which cleaves the acyl group from the coenzyme. If the esterase is cleavable into inactive peptide and protein fragments, it can be used as described earlier for RNase Spep/Spr. If it is not cleavable in that manner, it can be linked as a whole to the probe, e.g. directly, or by biotin/avidin, but preferably by RNase Spep/Spr. In this latter procedure, Spep is linked to the probe as described earlier, and Spr is linked to the enzyme. General methods for joining proteins are well known in the art, and can be used for linking the Spr fragment with the enzyme. This procedure, in which S-protein acts as a carrier for other enzymes can be represented as follows:

10 Key

Spr - Ex : S-protein containing a covalently bound enzyme molecule, Ex. Other species are as described earlier.


15 The following description is of procedures that employ pyridoxal phosphate and flavin coenzymes but any appropriate cofactor could be used to generate other detection systems.

Systems with pyridoxal as the coupling coenzyme

20 With this procedure the final detection system would be identical to that described earlier. The primary catalyst, attached to the S-protein could be any of a wide selection of hydrolytic enzymes, such as proteases, peptidases, amidases or esterases, and especially thrombin or one of the 25 other specific proteases of the blood-clotting system. With thrombin as the primary catalyst (Ex), the synthetic prothrombin coenzyme-generating substrate S<sub>1</sub>C<sub>1</sub> could be

compounds such as VIII - X

5




10


where  $R_2$  is either H- or  $-PO(OH)_2$  and  $R_1$  is an acyl group designed in the light of the known specificity of thrombin to make the compound a good substrate for thrombin action (Magnusson (1971) and references therein). Hydrolysis of 15 VIII gives pyridoxamine (phosphate), and IX and X both release pyridoxal or pyridoxal phosphate. If the aldehyde (hydrate) group in IX and X is replaced with a  $-CH_2OH$  group and the coupling effected through pyridoxol oxidase, it should prove less inhibitory and less prone to oxidation.

20 Compounds VIII - X can be synthesised from  $R_1COOH$  and the pyridoxal derivative by straightforward methods such as those described by Harrison & Harrison (1971). Preparation of suitable  $R_1COOH$  derivatives would be as described by Liem & Scheraga (1974).

25 Structures of coenzyme-generating substrates for cholinesterase and compounds XI and XII:



5



where  $R = H$  or  $-P(OH)_2$

10


Substrates XI and XII can be synthesised by using one of the usual methods for esterification (Harrison & Harrison (1971)) following protection of the appropriate groups in pyridoxal. To avoid any reaction of the aldehyde group of 15 pyridoxal (shown above as the hydrate) with a group in the active site of cholinesterase, pyridoxol can be the leaving group and pyridoxol oxidase and the kinase used as modifying enzymes as described earlier.

20 Systems with flavin derivatives as the coupling coenzymes

Such systems would use the end-detectors for flavin-coupled assays described earlier and the primary catalysts described in the previous section. The types of substrates 25 ( $S_1C_1$ ) that would be employed would have structure XIV for the thrombin action and XV for the case where cholinesterase

is the primary catalyst:

5



XIV,  $R_1$  = peptide fragment

$$XV, R_1 = \text{CH}_3$$

10

Chemical syntheses of the esters XIV and XV are by one of the methods described by Harrison & Harrison (1971); for example carbodiimide-mediated esterification of flavin with  $\text{CH}_3\text{COCl}$  and  $\text{DCCl}$ , with purification of the

### 15 substrate by HPLC.

REFERENCES

Arrio-Dupont, M. (1972) European J. Biochem. 30, 307.

5 Barnard, E.A. & Witzel, H. (1962) Biochem. Biophys. Res. Commun. 7, 289.

Brown, D.M. & Todd, A.R. (1953) J. Chem. Soc. 2040.

10 Chavers, L.G. & Scheraga, H.A. (1980) Biochemistry 19, 996.

Cheng, S.-Y., Clenn, T.M. and Pastan, I. (1983) Nucl. Acids Res. 11, 659.

15 Choong, Y.S., Shepherd, M.G. & Sullivan, P.A. (1975) Biochem. J. 145, 37.

Doscher, M.S. (1969) Methods in Enzymology 11, 640.

20 Findlay et al. 1962 - see elsewhere.

Froede, H.C. & Wilson, I.B. (1971) in "The Enzymes", 3rd Ed. ed Boyer V 87.

25 Fujikawa, K. & Davie, E.W. (1976) Methods in Enzymol. XLV, 89.

Gait, M.J., Matthes, H.W.D., Singh, M., Sproat, B. & Titmas, R.C.

in EMBO Course Manual (1982) Publ. Verlag Chemie.

Ghisla, S., Ogata, H., Massey, V., Schonbrunn, A., Abeles, R.H. & Walsh, C.T. (1976) Biochemistry 15, 1791.

5

Gibson, K.D., Neuberger, A. & Scott, J.J. (1955) Biochem. J. 61, 618.

Harrison, I.T. & Harrison, S.H. (1971) in "Compendium of  
10 Organic Synthetic Methods" pp. 280-286 and 204-207 and  
213-218.

Itakura, K., Katagiri, N., Narang, S.A., Bahl, C.P., Marians, K.J. & Wu, R. (1975) J. Biol. Chem. 250, 4592.

15

Itakura, K., Katagiri, N., Bahl, C.P., Wightman, R.H. & Narang, S.A. (1975) J. Am. Chem. Soc. 97, 7327.

20

Jesty, J. & Nemerson, Y. (1976) Methods in Enzymol. XLV, 95.

Liem, R.K.H. & Scheraga, H.A. (1974) Archives Biochem. Biophys. 160, 333.

25

Magnusson, S. (1971) in "The Enzymes" III (rd ed) ed.  
Boyer, P.D. p.278.

Marfrey, P.S., Nowak, H., Uziel, M. & Yphantis, D.A. (1965) J. Biol. Chem. 240, 3264 & 3270.

5 Martinez-Carrion, M., Tiemeier, D.C. & Peterson, D. (1970) Biochemistry 9, 2574.

Massey, V. & Curti, B. (1966) J. Biol. Chem. 241, 3417.

10 Mayhew, S.G. & Wassink, J.H. (1980) Methods in Enzymol. 66, 217.

Mayhew, S.G. & Wassink, J.H. (1980) Methods in Enzymol. 66, 323.

15 McCormick, D.B. (1962) J. Biol. Chem. 237, 959.

Merrill, A.H. & McCormick, D.B. (1978) Anal. Biochem. 89, 87.

20 Merrill, A.H. & McCormick, D.B. (1980) Methods in Enzymol. 66, 287.

Nakano, M., Ushijima, Y., Saga, M., Tsutsumi, Y. & Asami, H. (1968) Biochim. Biophys. Acta 167, 9.

25 Rej.R. (1982) Anal. Biochem. 119, 205.

Richards, F.M. & Vithayathil, P.J. (1959a) J. Biol. Chem. 234,  
1459.

Richards, F.M. & Vithayathil, P.J. (1959b) Brookhaven Symp. in  
5 Biol. 13, 115.

Roychoudhury, R., Jay, E. & Wu, R. (1976) Nucl. Acids Res. 3,  
863.

10 Schoellman, G. & Shaw, E. (1962) Biochem. Biophys. Res. Commun.  
7, 36.

Schrecker, A.W. & Scott, J.J. (1955) Biochem. J. 61, 618.

15 Schuman, M. & Massey, V. (1971) Biochim. Biophys. Acta 227,  
500.

Shin, M. (1971) Methods in Enzymol. 23A, 440.

20 Stawinski, J., Hozumi, Y., Narang, S.A., Bahl, C.P. & Wu, R.  
(1977) Nucleic Acids Res. 4, 353.

Swell, L., Law, M.D., Field, H. & Treadwell, C.R. (1960) Biochim.  
Biophys. Acta 235.

25

Takahashi, T., Irie, M. & Ukita, T. (1969) J. Biochem. (Tokyo)  
65, 55.

Todrick,A. (1954) Brit. J. Pharmacol. 9, 76.

Tsuge,H. & Nakanishi,Y. (1980) Methods in Enzymol. 66, 344.

5 Udaka,S., Koukol,J. & Vennesland,B. (1959) J. Bacteriol. 78,  
714.

Ward,D.C., Waldrop,A.A. III, Langer,P.A., (1982) EP 63879.

10 Wightman,R.H. & Narang,S.A. (1975) Nucleic Acids Res. 4,  
353.

Eckstein,F., Saenger,W. & Suck,D. (1972) Biochem. Biophys.  
Res. Comm. 46, No.2, 964-971.

15

Still,W.C., Kahn,M & Mitra,A. (1978) J. Org. Chem. 43,  
No.14, 2923-2925.

20 Usher,D.A., Erenrich,E.S. & Eckstein,F. (1972) Proc. Nat.  
Acad. Sci. U.S.A. 69, No.1, 115-118.

CLAIMS

1. A method of detecting an analyte in a sample medium, involving the use of an assay component carrying an enzymically inactive small fraction of a primary enzyme, and the addition of a complementary enzymically inactive protein fraction of the enzyme so as to conjugate to said small fraction and produce an active primary enzyme, and the performance of a reaction catalysed by said enzyme, leading 10 to a detectable result; characterised in that said assay component is a specific recognition probe which binds to the analyte, and said primary enzyme catalyses a reaction which converts a substrate into a primary product which itself, or as a subsequent product produced by a further reaction or 15 series of reactions initiated by said primary product, is an essential component of a second enzyme which is thereby completed and catalyses a reaction leading to a detectable result.

20 2. A detection method according to claim 1 wherein said small fraction of the primary enzyme is a minor peptide fraction of the total enzyme protein.

3. A detection method according to claim 2 wherein said 25 small fraction is a ribonuclease S-peptide, and the complementary fraction is the ribonuclease S-protein.

4. A detection method according to claim 3 wherein the S-peptide and S-protein conjugate to form a ribonuclease S enzyme which catalyses a synthetic substrate to said primary product.

5

5. A detection method according to claim 4 wherein said synthetic substrate is a pyrimidine 3'-phosphodiester compound of the formula R-X wherein R is a pyrimidine 3'-phosphate moiety and X is a leaving group which forms 10 said primary product, X being linked to R through the 3'-phosphate group.

6. A method of detecting an analyte in a sample medium, involving the use of an enzymically inactive ribonuclease 15 S-peptide as a label to which is conjugated an enzymically inactive ribonuclease S-protein to form a ribonuclease enzyme, and the performance of a reaction catalysed by said ribonuclease enzyme to indicate the presence of analyte; characterised in that said ribonuclease catalysed reaction 20 is performed on a synthetic substrate of the formula R-X, wherein R is a pyrimidine 3'-phosphate moiety and X is a leaving group linked to R through the 3'-phosphate group, the leaving group product of the reaction being a cofactor or prosthetic group for a second enzyme, or a precursor for 25 said cofactor or prosthetic group, and a reaction catalysed by said second enzyme is carried out leading to a detectable result indicating the presence of analyte in the sample

medium.

7. A pyrimidine 3'-phosphodiester compound of the formula R-X, where R is a pyrimidine 3'-phosphate and X is a leaving group linked to R through the 3'-phosphate group, and cleavable therefrom to produce an essential component of an enzyme, or precursor therefor.

8. A detection method according to claim 5 or claim 6 or 10 an R-X compound of claim 7 wherein the leaving group product of the ribonuclease catalysed reaction is selected from riboflavin, thiamine, pyridoxal, pyridoxine and pyridoxine phosphate.

15 9. A detection method or R-X compound of claim 8 wherein said leaving group product is converted to a coenzyme or prosthetic group selected from flavin mononucleotide, flavin adenine dinucleotide, thiamine diphosphate and pyridoxal 5-phosphate.

20


10. A synthetic prosthetogen compound which is cleavable by an enzyme to produce a component essential for the catalytic activity of another enzyme, or a precursor therefor.

25 11. An enzyme linked immunoassay procedure in which a primary enzyme whose concentration is related to the presence of analyte to be detected catalyses a primary enzymic

reaction leading to a detectable product; characterised in  
that a substrate for the primary enzyme is a synthetic  
compound which is cleaved by the primary enzyme to produce  
directly, or by one or more further reactions, a component  
5 essential for the catalytic activity of another enzyme,  
which is thereby activated to catalyse a secondary enzymic  
reaction leading to a detectable result.

1/4


Fig. 1. The course of reaction for production of Cp riboflavin



1. Riboflavin (5 $\mu$ g).
- 2 (A). Control incubation (no RNase) Time point 0.
- (B). Incubation (+RNase) 0 time.
3. Cytidine 2',3'-cyclic phosphate (5 $\mu$ g).
- 4 (A). Control incubation (11 days).
- (B). Incubation (+RNase) 11 days.
5. CpA (5 $\mu$ g).
- 6 (A). Control incubation (31 days).
- (B). Incubation (+RNase) 31 days.


Chromatogram was viewed under u.v. light at 284 and 360 nm.

Fig. 2.



3/4


*Fig. 3.* Thin layer chromatogram of elution products from flash chromatography.



1. Riboflavin (5 $\mu$ g).	6. Peak II (flash chromatography).
2. Peak I (flash chromatography).	7. Riboflavin (5 $\mu$ g).
3. Cytidine 2',3'-cyclic phosphate (5 $\mu$ g).	 Fraction A = Rf 0.872.
4. Fraction A (flash chromatography).	
5. CpA (5 $\mu$ g).	

4/4

Fig. 4. Thin layer chromatogram of column fraction A after incubation with RNase ( $1\text{mg.ml}^{-1}$ )



1. Riboflavin ( $1.3 \times 10^{-4}\text{M}$ ) +  $1\text{mg.ml}^{-1}$  RNase A.
2. Riboflavin (5  $\mu\text{g}$ ).
3. Evaporated column fraction A +  $1\text{mg.ml}^{-1}$  RNase.
4. Evaporated column fraction A: No RNase.
5. Cytidine 2',3'-cyclic phosphate.
6. CpA (5  $\mu\text{g}$ )





Europäisches Patentamt  
European Patent Office  
Office européen des brevets

⑪ Publication number:

**0 156 641**  
A3

⑫ **EUROPEAN PATENT APPLICATION**

㉑ Application number: **85302045.1**

㉓ Int. Cl.4: **G 01 N 33/58, G 01 N 33/53,**  
**C 12 Q 1/34**  
**// C12Q1/68**

㉒ Date of filing: **25.03.85**

㉔ Priority: **26.03.84 GB 8407736**

㉕ Applicant: **London Biotechnology Limited, Temple Court 11 Queen Victoria Street, London E2N 4TP (GB)**

㉖ Date of publication of application: **02.10.85**  
**Bulletin 85/40**

㉗ Inventor: **Rabin, Brian Robert, 34 Grangewood Potters Bar, Hertfordshire (GB)**  
Inventor: **Taylorson, Christopher John, 31 Bath Road, Chiswick London, W4 (GB)**  
Inventor: **Hollaway, Michael Robert, 214 Ember Lane, East Molesey Surrey (GB)**

㉘ Designated Contracting States: **AT BE CH DE FR GB IT LI LU NL SE**

㉙ Representative: **Armitage, Ian Michael et al, MEWBURN ELLIS & CO. 2/3 Cursitor Street, London EC4A 1BQ (GB)**

㉚ **Enzymic method of detecting analytes and novel substrates therefor.**

㉛ **A3**  
A small enzymically inactive peptide fragment of an enzyme (e.g. ribonuclease S-peptide) is used as the label and conjugated with the complementary fragment (S-protein) to form an enzyme which catalyses a primary reaction whose product is, or leads to, an essential coenzyme or prosthetic group for a second enzyme which catalyses a secondary reaction leading to a detectable result indicating the presence of analyte. Also disclosed are novel synthetic substrates for the primary reaction. Substrates for ribonuclease S conjugate enzyme are of the formula R-X where R is a pyrimidine 3'-phosphate moiety and X is a leaving group linked to R through the 3'-phosphate group and leads to said coenzyme or prosthetic group, e.g. via riboflavin, thiamine, pyridoxal, pyridoxine or pyridoxine phosphate.

**41 A3**

**EP 0 156 641**



European Patent  
Office

EUROPEAN SEARCH REPORT

0156641

Application number

EP 85 30 2045

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
X	EP-A-0 027 036 (SELF C.H.) * Page 8, lines 7-18; page 34, lines 1-7; page 57, lines 2-16 *	1, 2, 11	G 01 N 33/58 G 01 N 33/53
X	EP-A-0 123 265 (E.I. DU PONT DE NEMOURS) * Page 5, line 26 - page 10, line 16; page 58, lines 15-36 *	1, 2	-
X	GB-A-1 401 297 (SYNTEX ENERGY RESEARCH INC., VARIAN ENERGY) * Page 2, line 36 - page 3, line 33; page 21, table *	1, 2	
X	US-A-4 463 090 (HARRIS C.C.) * Column 2, line 44 - column 4, line 24 *	1, 2	
X	US-A-3 852 157 (SYVA CORP.) * Column 2, lines 39-57; column 30, table *	1, 2	C 12 Q 1/00 G 01 N 33/00
X, D	WO-A-8 100 725 (PRINCE CHARLES HOSPITAL DEVELOPMENT CENTRE TRUST) * Page 7, line 28 - page 8, line 21; page 17, lines 2-23 *	1, 2	
	---	-/-	
The present search report has been drawn up for all claims			

Place of search  
THE HAGUE

Date of completion of the search  
26-08-1987

Examiner  
VAN BOHEMEN C.G.

CATEGORY OF CITED DOCUMENTS

X : particularly relevant if taken alone  
Y : particularly relevant if combined with another document of the same category  
A : technological background  
O : non-written disclosure  
P : intermediate document

T : theory or principle underlying the invention  
E : earlier patent document, but published on, or after the filing date  
D : document cited in the application  
L : document cited for other reasons  
& : member of the same patent family, corresponding document



EUROPEAN SEARCH REPORT

0156641

Application number

EP 85 30 2045

DOCUMENTS CONSIDERED TO BE RELEVANT			Page 2
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
X, D	EP-A-0 027 036 (SELF C.H.) * Page 15, diagram; page 57, lines 2-16 * -----	1, 2	
TECHNICAL FIELDS SEARCHED (Int. Cl.4)			
The present search report has been drawn up for all claims			
Place of search THE HAGUE	Date of completion of the search 26-08-1987	Examiner VAN BOHEMEN C.G.	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

**This Page Blank (uspto)**